Please assess the completion status of the following clinical trial:

Trial Title: A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HIV-1-infection ≥3 months prior to screening~* Participants with female partner(s) of child-bearing potential must agree to use a medically acceptable method of contraception during the study and for 90 days after the last dose of study drug~* Body Mass Index (BMI) ≤35 kg/m\^2~* Other than HIV infection, participant's baseline health is judged to be stable~* No clinically significant abnormality on electrocardiogram (ECG)~* Participant is ART-naïve (defined as having never received any antiretroviral agent or ≤30 consecutive days of an investigational antiretroviral agent (excluding an Non-Nucleoside Reverse Transcriptase Inhibitor \[NNRTI\]) or ≤60 consecutive days of combination ART not including an NNRTI)~* Participant is willing to receive no other ART for the duration of the treatment phase of this study.~Exclusion Criteria:~* History of stroke, chronic seizures, or major neurological disorder~* History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological (outside of HIV-1 infection), renal, respiratory, or genitourinary abnormalities or diseases~* History of clinically significant neoplastic disease~* Participant has used any immune therapy agents or immunosuppressive therapy within 1 month prior to treatment in this study~* Participant has one or more pre-existing risk factors for Torsades de Pointes (New York Heart Association Functional Classification II through IV heart failure, familial long-QT-syndrome, uncorrected hypokalemia, QTcF \>470 msec)~* Participant requires or is anticipated to require chronic daily prescription medications~* Current (active) diagnosis of acute hepatitis due to any cause~* History of chronic Hepatitis C virus (HCV) unless there has been documented cure and/or patient with a positive serologic test for HCV has a negative HCV viral load.~* Positive Hepatitis B surface antigen~* Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort \[Hypericum perforatum\]) beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study, until the post-study visit~* Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 mL/10 ounces\], wine \[125 mL/4 ounces\], or distilled spirits \[25 mL/1 ounce\]) per day~* Participant consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day~* Participant is an excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to restrict smoking to ≤10 cigarettes per day~* Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit~* Participation in another investigational study within 4 weeks prior to the prestudy (screening) visit~* History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food~* Current regular user (including use of any illicit drugs) or has a history of drug (including alcohol) abuse within approximately 1 year

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Panel A: Doravirine 25 mg or Placebo (Type: EXPERIMENTAL): Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
- Panel B: Doravirine 200 mg or Placebo (Type: EXPERIMENTAL): Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
- Panel C: Doravirine or Placebo (Type: EXPERIMENTAL): Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.

Based on this trial design, predict the completion outcome and termination type (if applicable).